BSE · RAMAVISION.BO
Rama Vision Limited
₹174.40-₹5.80 (-3.22%)
Rama Vision Limited’s quoted price sits in the upper half of its reported 52-week range, 8.62% below the high.
Loading market information…
NSE · MANGALAM.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:13 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Mangalam Drugs & Organics Limited’s quoted price sits in the lower half of its reported 52-week range, 57.62% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Mangalam Drugs & Organics Limited’s forward annual dividend is ₹0.20 per share, paid annual. The forward yield is 0.69% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Mangalam Drugs & Organics Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Mumbai, India, Mangalam Drugs & Organics Limited, established in 1972, operates as a global pharmaceutical enterprise. The company is engaged in the production and distribution of a diverse range of medications, drugs, and associated pharmaceutical goods, serving both domestic Indian and international markets. Its offerings encompass various active pharmaceutical ingredients (APIs), chemical intermediates, specialized compounds, and impurities, which are crucial for treatments targeting conditions such as malaria, pain and inflammation, high blood pressure, and retroviral infections.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹174.40-₹5.80 (-3.22%)
Rama Vision Limited’s quoted price sits in the upper half of its reported 52-week range, 8.62% below the high.
₹82.00+₹0.99 (+1.22%)
Jeevan Scientific Technology Limited’s quoted price sits in the upper half of its reported 52-week range, 12.67% below the high.
₹114.67-₹6.03 (-5.0%)
Par Drugs and Chemicals Limited’s quoted price sits in the lower half of its reported 52-week range, 36.29% below the high.
₹82.00-₹2.61 (-3.08%)
Bal Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 34.19% below the high.
₹57.50-₹0.43 (-0.74%)
Krebs Biochemicals & Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 25.18% below the high.
₹6.86+₹0.04 (+0.59%)
Vaishali Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 34.54% below the high.
₹734.00₹0.00 (0.0%)
Mercury Laboratories Limited’s quoted price sits in the lower half of its reported 52-week range, 20.95% below the high.
₹9.05+₹0.10 (+1.12%)
Bharat Immunologicals & Biologicals Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 59.97% below the high.
